Deterioration of Glycemic Control Contributes to the Prevalence of Proteinuria among Bevacizumab-Treated Cancer Patients with Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Deterioration of Glycemic Control Contributes to the Prevalence of Proteinuria among Bevacizumab-Treated Cancer Patients with Type 2 Diabetes Mellitus

Published:2018-11-01 Issue:11 Volume:41 Page:1722-1726
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Chiba Takeshi¹²,Nihei Satoru¹²,Komatsu Hideaki³,Obara Mami²,Ishigaki Yasushi⁴,Sasaki Akira⁴,Kudo Kenzo¹²

Affiliation:

1. Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University

2. Department of Pharmacy, Iwate Medical University Hospital

3. Department of Surgery, School of Medicine, Iwate Medical University

4. Division of Diabetes and Metabolism, Department of Internal Medicine, School of Medicine, Iwate Medical University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/41/11/41_b18-00493/_pdf

Reference20 articles.

1. 1) Ferrara N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol., 29, 789–791 (2009).

2. 2) Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57, 4593–4599 (1997).

3. 3) Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol., 26, 2013–2019 (2008).

4. 4) Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol., 25, 4779–4786 (2007).

5. 5) Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J. Clin. Oncol., 27, 4787–4792 (2009).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of Factors Affecting Proteinuria Onset Timing in Patients Treated with Bevacizumab;YAKUGAKU ZASSHI;2022-06-01

2. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib;Biological and Pharmaceutical Bulletin;2022-03-01